HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Psychiatry · Weight Management Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Psychiatry · Weight Management Therapeutic Area Assessment

51 signals · 5 insights · 201 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 62%

Evidence

257 items

Sources

3

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Psychiatry · Weight Management integrates 51 signals, 5 executive insights, and 201 regulatory precedents from the Humanexa intelligence graph. 1 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJun 16, 2026

    Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients

    A Phase III trial demonstrated that Ashwagen® significantly reduced anxiety and stress markers in patients with hypertension.

    View detail
  2. signalJul 23, 2026

    University of Maryland Evaluates Suvorexant for Reducing Drug Demand

    A clinical trial is underway to assess the efficacy of suvorexant in reducing drug demand and subjective liking.

    View detail
  3. signalJul 23, 2026

    Post-ICU PTSD Intervention Shows Potential for Improving Quality of Life

    A secondary analysis of the PICTURE trial indicates that a brief primary care intervention may improve health-related quality of life in ICU survivors with PTSD symptoms.

    View detail
  4. signalJul 23, 2026

    Heritage Pharma's Sertraline Hydrochloride ANDA077345 Receives AP Status

    Heritage Pharma's application for Sertraline Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

    View detail
  5. regulatoryJul 23, 2026

    Drug Trials Snapshots: ZYCUBO

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Suvorexant.

    View detail
  6. regulatoryJul 23, 2026

    Drug Trials Snapshots: VOYXACT

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Suvorexant.

    View detail
  7. regulatoryJul 23, 2026

    Drug Trials Snapshots: YARTEMLEA

    YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

    View detail
  8. regulatoryJul 23, 2026

    Drug Trials Snapshots: PALSONIFY

    PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

    View detail
  9. insightJun 24, 2026

    FDA Acceptance of Fluoxetine Hydrochloride Signals Competitive Shift in Antidepressants

    The FDA's acceptance of Sciegen Pharmaceuticals' supplemental application for Fluoxetine Hydrochloride is a significant regulatory milestone that could reshape competitive dynamics in the antidepressant market. Portfolio teams should closely monitor this development to understand its implications for market positioning and competitive strategy. Regulatory context from FDA (FDA AP — FLUOXETINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (2 high-relevance).

    View detail
  10. insightJun 21, 2026

    Emerging Generic Competition in Psychiatry: Strategic Implications for Market Leaders

    Hikma's receipt of Abbreviated Approval for Levomilnacipran Hydrochloride signifies a new entrant in the SNRI market, which could disrupt pricing and market dynamics. This development necessitates close monitoring of competitor responses and market shifts as Hikma prepares for launch. Regulatory context from FDA (FDA AP — LEVOMILNACIPRAN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (20 high-relevance).

    View detail
  11. insightJun 19, 2026

    Emerging Insights in Pediatric Mental Health: Implications for Treatment Strategies

    This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies. Regulatory context from FDA (FDA AP — CHILDREN'S CLARITIN (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (13 high-relevance).

    View detail
  12. insightJun 10, 2026

    Emerging Opportunities in Psychiatry: Innovations in Treatment and Regulatory Landscape

    The efficacy of Ashwagen® in managing stress and anxiety in hypertensive patients presents a significant opportunity for pharma companies to enhance their portfolios in the mental health space. This finding could lead to the development of new treatment protocols and integration into existing guidelines, impacting both clinical practice and market positioning. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 6 ranked evidence items (3 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 5 risk-calibrated assessments for portfolio review. 201 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 8 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Drug Trials Snapshots: ZYCUBO

    72%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Suvorexant.

    Source: FDA

    View evidence

  • Drug Trials Snapshots: VOYXACT

    72%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Suvorexant.

    Source: FDA

    View evidence

  • Drug Trials Snapshots: YARTEMLEA

    72%

    YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

    Source: FDA

    View evidence

  • Drug Trials Snapshots: PALSONIFY

    72%

    PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

    Source: FDA

    View evidence

  • Drug Trials Snapshots

    72%

    Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots are part of an overall FDA effort to make demographic data more available and transparent.

    Source: FDA

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    77%

    Application ANDA078783. Sponsor: STRIDES PHARMA INTL. Submission status: AP. Submission type: SUPPL. Active ingredients: TRAMADOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA Acceptance of Fluoxetine Hydrochloride Signals Competitive Shift in Antidepressants

    51%

    The FDA's acceptance of Sciegen Pharmaceuticals' supplemental application for Fluoxetine Hydrochloride is a significant regulatory milestone that could reshape competitive dynamics in the antidepressant market. Portfolio teams should closely monitor this development to understand its implications for market positioning and competitive strategy. Regulatory context from FDA (FDA AP — FLUOXETINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (2 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Generic Competition in Psychiatry: Strategic Implications for Market Leaders

    69%

    Hikma's receipt of Abbreviated Approval for Levomilnacipran Hydrochloride signifies a new entrant in the SNRI market, which could disrupt pricing and market dynamics. This development necessitates close monitoring of competitor responses and market shifts as Hikma prepares for launch. Regulatory context from FDA (FDA AP — LEVOMILNACIPRAN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (20 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Insights in Pediatric Mental Health: Implications for Treatment Strategies

    57%

    This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies. Regulatory context from FDA (FDA AP — CHILDREN'S CLARITIN (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (13 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Opportunities in Psychiatry: Innovations in Treatment and Regulatory Landscape

    66%

    The efficacy of Ashwagen® in managing stress and anxiety in hypertensive patients presents a significant opportunity for pharma companies to enhance their portfolios in the mental health space. This finding could lead to the development of new treatment protocols and integration into existing guidelines, impacting both clinical practice and market positioning. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 6 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Torrent Pharmaceuticals Gains Competitive Edge with Lurasidone Hydrochloride Approval

    69%

    Torrent's receipt of Abbreviated Approval (AP) for Lurasidone Hydrochloride positions the company to enhance its competitive stance in the antipsychotic market. This development necessitates strategic planning for portfolio expansion and pricing adjustments to counteract potential responses from established players. Regulatory context from FDA (FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients

    Trial Update

  • University of Maryland Evaluates Suvorexant for Reducing Drug Demand

    Trial Update

  • Post-ICU PTSD Intervention Shows Potential for Improving Quality of Life

    Trial Update

  • Heritage Pharma's Sertraline Hydrochloride ANDA077345 Receives AP Status

    Regulatory Approval

  • Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety Trial Initiated

    Trial Update

  • FDA Grants Approval for Lurasidone Hydrochloride ANDA208047 by Dr. Reddy's

    Regulatory Approval

  • Phase II Trial of Teleo Virtual Therapy Platform for Youth Psychotherapy Engagement

    Trial Update

  • Aurobindo Pharma's Olanzapine ANDA203708 Receives AP Status from FDA

    Regulatory Approval

Insights

  • FDA Acceptance of Fluoxetine Hydrochloride Signals Competitive Shift in Antidepressants

    Psychiatry · Antidepressant

  • Emerging Generic Competition in Psychiatry: Strategic Implications for Market Leaders

    Psychiatry · SNRI

  • Emerging Insights in Pediatric Mental Health: Implications for Treatment Strategies

    Psychiatry · PTSD

  • Emerging Opportunities in Psychiatry: Innovations in Treatment and Regulatory Landscape

    Psychiatry · Stress and Anxiety

  • Torrent Pharmaceuticals Gains Competitive Edge with Lurasidone Hydrochloride Approval

    Psychiatry · Antipsychotic

Companies

  • Pfizer

    140 signals

  • Eli Lilly

    78 signals

  • Hikma

    30 signals

  • Aurobindo Pharma

    28 signals

  • Sciegen Pharmaceuticals

    15 signals

  • Alembic Pharmaceuticals

    14 signals

  • Zydus Pharmaceuticals

    11 signals

  • Amneal Pharmaceuticals

    9 signals

Assets

  • Lurasidone Hydrochloride
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.